biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
ID1.2, monoclonal
species reactivity
human
should not react with
bovine, rat, pig
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable, immunocytochemistry: suitable, immunohistochemistry: suitable (paraffin), radioimmunoassay: suitable, western blot: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... IBSP(3381)
pig ... Ibsp(397137)
rat ... Ibsp(24477)
General description
Bone Sialoprotein II is one of the major noncollagenous proteins in the extracellular matrix of bone. It is a phosphorylated glycoprotein with an approximate molecular weight of 70 kDa. The protein has been found in osteoblasts and osteocytes. Diseases concerning bone turnover, pathological bone alterations, as well as the rapid increase of osteoporosis make it necessary to establish new markers. Bone Sialoprotein is discussed as a potential serum marker for monitoring bone remodeling.
Immunogen
Bone Sialoprotein isolated from human bones.
Epitope: C-terminus
Application
Research Category
Cell Structure
Cell Structure
Research Sub Category
Osteobiology
Osteobiology
This Anti-Bone Sialoprotein II Antibody, C-terminus, clone ID1.2 is validated for use in ELISA, RIA, WB, IC, IH(P) for the detection of Bone Sialoprotein II.
Western blot: (1μg/mL)
Immunohistochemistry on paraffin embedded tissue sections: (1μg/mL)
Immunocytochemistry: (1:100)
ELISA: (1μg/mL)
RIA
Optimal working dilutions must be determined by the end user.
Immunohistochemistry on paraffin embedded tissue sections: (1μg/mL)
Immunocytochemistry: (1:100)
ELISA: (1μg/mL)
RIA
Optimal working dilutions must be determined by the end user.
Biochem/physiol Actions
Recombinant and native human bone sialoprotein II (BSPII). Does not react with osteopontin (BSPI) or osteonectin.
Physical form
Format: Purified
Purified immunoglobulin from culture supernatant. Lyophilized from 50 mM TRIS, pH7.4.
Preparation Note
Maintain lyophilized material at 2-8°C. Reconstitute with 100μL sterile distilled water and store at -20°C in undiluted aliquots up to 12 months. Avoid repeated freeze/thaw cycles.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Replaces: AB1855
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
存储类别
10 - Combustible liquids
wgk
WGK 1
Strategies for accelerating osteogenesis through nanoparticle-based DNA/mitochondrial damage repair.
Hye Jin Kim et al.
Theranostics, 12(14), 6409-6421 (2022-09-29)
The efficiency of gene therapy is often dictated by the gene delivery system. Cationic polymers are essential elements of gene delivery systems. The relatively cheap cationic polymer, polyethyleneimine, has high gene delivery efficiency and is often used for gene delivery.
Liisa T Kuhn et al.
Tissue engineering. Part A, 20(1-2), 365-377 (2013-08-21)
The in vivo osteogenesis potential of mesenchymal-like cells derived from human embryonic stem cells (hESC-MCs) was evaluated in vivo by implantation on collagen/hydroxyapatite scaffolds into calvarial defects in immunodeficient mice. This study is novel because no osteogenic or chondrogenic differentiation
Xiaonan Xin et al.
Stem cells translational medicine, 3(10), 1125-1137 (2014-08-15)
The use of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) for study and treatment of bone diseases or traumatic bone injuries requires efficient protocols to differentiate hESCs/iPSCs into cells with osteogenic potential and the ability to
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| MAB1061 | 04053252726880 |